De ce cresc acțiunile SANOFI?
Argumentele cumpărătorilor
Key product momentum
Strong Dupixent sales are driving unexpected revenue growth and sustained commercial momentum, supported by favorable U.S. reimbursement dynamics that improve patient access.
Guidance revision
Company raised sales guidance while keeping earnings guidance in line with expectations, signaling management expects continued top-line strength without materially changing profitability targets.
Valuation and strategic optionality
Analyst notes the stock appears undervalued relative to peers and a disciplined acquisition strategy to rebuild the pipeline could unlock upside if deal execution and asset selection improve.
Earnings quality
Earnings per share missed expectations due to weaker other operating income, and reported margin improvement was partly driven by one‑off accounting items, raising questions about the sustainability of reported profits.
Commercial execution
Shipment delays for Nexviazyme and competitive pressure slowing Beyfortus adoption have trimmed near‑term sales and highlight execution risk for key product rollouts.
R&D and pipeline uncertainty
Change in senior leadership, limited strategic detail from the new CEO, a new head of research with a mixed track record, and a recent halt of a late‑stage immunology program increase uncertainty around future drug progress and suggest a multi‑year pipeline turnaround may be needed.
